Care of the Prostate Cancer Patient and Prospective Procurement of Prostate Cancer Tissue

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
Age18+
SponsorNational Cancer Institute (NCI)

About this trial

Background:

Prostate cancer is the most common noncutaneous cancer among men in the U.S. Researchers want to study blood, tissue, and fluid samples of people with prostate cancer. This will help them understand any changes in cells and genes. These changes might lead to the development and progression of prostate cancer. Researchers think the study could lead to new treatments.

Objective:

To understand the changes in cells and genes that lead to the development and progression of prostate cancer. This could lead to new treatments.

Eligibility:

Men ages 18 and older who have or are suspected to have prostate cancer

Design:

Participants will be screened with physical exam and medical history.

Participants will send tissue blocks of their tumor, if possible. If not, they will provide unstained slides of tumor tissue.

Participants may provide samples of blood, urine, saliva, and prostate secretions.

Participants may have imaging tests. They will lie in a machine that takes pictures of their body. These tests include:

MRI of the prostate

CT of the abdomen and pelvis

Chest x-ray

Participants may need a biopsy or surgery for treatment of their cancer. If so, researchers will collect tissue.

Participants may answer questions about their prostate cancer and quality of life.

Participants may have follow-up visits or other treatments. They may have follow-up phone calls every few months.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Adults (greater than or equal to 18 years of age) with biopsy-proven or suspected prostate cancer (elevated PSA abnormal digital rectal exam (DRE) abnormal prostate MRI, or family history) who require and are willing to undergo diagnostic or therapeutic intervention as part of their diagnosis, standard of care treatment, or follow-up/surveillance for their neoplasm.

ECOG performance status of 0-2

Must be willing and able to provide informed consent

PSA > or equal to 1.0 ng/ml (for patients aged 30 - 49 years) OR

Disqualifiers

None

Trial population

Adults with biopsy-proven or suspected prostate cancer who require diagnostic or therapeutic intervention as part of their diagnosis, standard of care treatment, or follow-up/surveillance for their neoplasm.

Trial design

Design model

Case-only

Time perspective

Prospective

Treatments tested in this trial

Not listed

Trial groups

3,000 Participants
are grouped into 1 trial group
Group A: 1

Trial outcomes

Primary outcomes

1

Collect samples for the purpose of studying the molecular mechanisms of carcinogenesis in prostate cancer

Collection of blood, urine, saliva, expressed prostatic secretions, and benign and malignant tissue

Time frame
Ongoing

Secondary outcomes

1

prostate cancer cell lines

Develop stable prostate cancer cell lines from procured tissue when feasible

Time frame
ongoing
2

Natural history of prostate cancer

Collect detailed history, pathologic data, perioperative findings, and treatment data to better characterize the natural and clinical histories of prostate cancer when feasible

Time frame
ongoing
3

Molecular profiling

whole genomic sequence characterizations, identification of specific mutations or single nucleotide polymorphisms (SNPs), comparative genomic hybridization, messenger and microRNA sequencing and expression, RNA Seq, DNA methylation (epigenetics), DNA copy number, and expression profiling

Time frame
ongoing

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.